{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000049","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.809874+00:00","generated_at":"2026-05-30T07:17:30.214276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth","bullets":["Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).","GAAP diluted EPS $1.05 (+72% YoY); Non-GAAP diluted EPS $1.27 (+69% YoY).","2024 guidance raised: revenue $970M-$1.02B, Adj. EBITDA $595M-$625M, Non-GAAP EPS $4.00-$4.20.","argenx expanded ENHANZE deal (4 new targets) for $30M upfront; ViiV added another target.","Cash and securities $666.3M, up from $336M at Dec 2023, driven by operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000049","json":"https://secwatch.observer/filing/0001159036-24-000049.json","markdown":"https://secwatch.observer/filing/0001159036-24-000049.md","text":"https://secwatch.observer/filing/0001159036-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/0001159036-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/halo-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:17:30.214276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}